GBIO Key Statistics, Chart & Performance
The current stock price of GBIO is 5.685 USD. In the past month the price increased by 3.93%. In the past year, price decreased by -39.36%.
GBIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GBIO. When comparing the yearly performance of all stocks, GBIO is a bad performer in the overall market: 86.49% of all stocks are doing better.
GBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GBIO. The financial health of GBIO is average, but there are quite some concerns on its profitability.
GBIO Financial Highlights
Over the last trailing twelve months GBIO reported a non-GAAP Earnings per Share(EPS) of -9.34. The EPS increased by 57.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.38% | ||
| ROE | -123.87% | ||
| Debt/Equity | 0 |
GBIO Forecast & Estimates
11 analysts have analysed GBIO and the average price target is 9.01 USD. This implies a price increase of 58.49% is expected in the next year compared to the current price of 5.685.
For the next year, analysts expect an EPS growth of 33.1% and a revenue growth -39.28% for GBIO
GBIO Ownership
About GBIO
Company Profile
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. The company focuses on targets in T cells that are undruggable or poorly drugged. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
Company Info
GENERATION BIO CO
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Geoff McDonough
Employees: 115
Phone: 16176557500
GENERATION BIO CO / GBIO FAQ
Can you describe the business of GENERATION BIO CO?
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. The company focuses on targets in T cells that are undruggable or poorly drugged. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
Can you provide the latest stock price for GENERATION BIO CO?
The current stock price of GBIO is 5.685 USD. The price decreased by -0.09% in the last trading session.
What is the dividend status of GENERATION BIO CO?
GBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of GBIO stock?
GBIO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does GENERATION BIO CO belong to?
GENERATION BIO CO (GBIO) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of GBIO stock?
GENERATION BIO CO (GBIO) has a market capitalization of 38.32M USD. This makes GBIO a Nano Cap stock.
Can you provide the short interest for GBIO stock?
The outstanding short interest for GENERATION BIO CO (GBIO) is 0.65% of its float.